BMJ Open Gastroenterology · 2017 · 60 citations · 8 references
Life SciencesImmunologyPharmacotherapyImmunotherapyInflammationRheumatologyAutoimmune Rheumatic DiseasesGastrointestinal InflammationInflammatory Bowel DiseaseInflammatory Disease PharmacotherapyMucosal InflammationUlcerative Colitis PharmacotherapyCombination TherapyCombination Therapy EffectsDrug Combination TherapyInflammatory Bowel Disease ImmunopathogenesisInflammatory Bowel Disease TherapyVedolizumab Therapy
Inflammatory bowel disease is frequently associated with spondylarthritis (SpA). It has been discussed that α4/β7 expressing lymphocytes are involved in the aetiology of SpA. We report a case of a successful combination therapy of vedolizumab (VDZ) and etanercept (ETA) in a patient with ulcerative colitis with pouchitis and SpA. In our case VDZ was effective for pouchitis and ineffective for SpA. The combination with ETA might be a useful treatment strategy to control both diseases and first indications suggest that it is safe. α4/β7 Expressing lymphocytes are most likely not associated in the aetiology of SpA.
8
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan, Paul Rutgeerts, Bruce E. Sands et al. · New England Journal of Medicine · 2013 · 2.9K citations · Full text
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn, Brian G. Feagan, Paul Rutgeerts et al. · New England Journal of Medicine · 2013 · 2.7K citations · Full text
Daniel C. Baumgart, Bernd Bokemeyer, Attyla Drabik et al. · Alimentary Pharmacology & Therapeutics · 2016 · 184 citations · Full text